Compare SIF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIF | LUNG |
|---|---|---|
| Founded | 1913 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 72.2M |
| IPO Year | 1995 | 2020 |
| Metric | SIF | LUNG |
|---|---|---|
| Price | $14.19 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 151.6K | ★ 646.6K |
| Earning Date | 05-27-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.67 | 7.64 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $111,212,000.00 | $90,497,000.00 |
| Revenue This Year | N/A | $6.20 |
| Revenue Next Year | N/A | $21.61 |
| P/E Ratio | $50.24 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $2.33 | $1.31 |
| 52 Week High | $15.00 | $8.10 |
| Indicator | SIF | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 54.59 |
| Support Level | $5.92 | $1.44 |
| Resistance Level | N/A | $1.97 |
| Average True Range (ATR) | 1.25 | 0.17 |
| MACD | -0.20 | 0.04 |
| Stochastic Oscillator | 57.68 | 47.33 |
SIFCO Industries Inc produces forgings, sub-assemblies, and machined components for the Aerospace and Energy markets. Its services include forging, heat treating, machining, surface treatment, non-destructive testing, and sub-assembly of forged components. The company manufactures envelopes and precision forgings, as well as rough and finished machined parts, serving OEMs, Tier 1 and Tier 2 suppliers, and aftermarket providers across Aerospace, Defense, Energy, and Commercial Space. Its Products are made from steel, high-temperature alloys, nickel alloys, titanium, and aluminum, and include components for aircraft and industrial gas turbine engines, airframe structures, landing gear, wheels and brakes, helicopter rotating parts, and other commercial and industrial applications.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.